Discovery of Highly Selective and Potent Macrocyclic JAK2 Inhibitors for the Treatment of MPNs

outperforms both pacritinib and fedratinib in MPN models at lower doses. This work validates macrocyclization as an effective strategy for refining JAK2 inhibitors, simultaneously enhancing kinase selectivity, metabolic stability, and efficacy.